RxDoctor Payments Data

James McBride

Optometrist · Tullahoma, TNNPI 1700856267

Payments from drug & device makers

$3,703in general payments, 2019–2025

Across 115 payments — averaging $32.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$366
  • Bausch & Lomb Americas Inc.$291
  • AbbVie$246
  • Coopervision Inc.$234
  • Oyster Point Pharma, Inc.$229
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,68499%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,703 in reported general payments places this provider in the 85th percentile of 1,122 optometrist providers in Tennessee.

See all optometrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$149,235
Medicare patients
523
Services billed
2,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine41$57,169
XiidraLifitegrast49$56,707
RocklatanNetarsudil Mesylat/Latanoprost61$34,987
XdemvyLotilaner14$25,718
LumiganBimatoprost28$18,229
VyzultaLatanoprostene Bunod29$13,249
CequaCyclosporine16$11,273
CombiganBrimonidine Tartrate/Timolol19$5,299
Brinzolamide20$3,761
Brimonidine Tartrate20$2,677
Travoprost12$1,500
Latanoprost116$1,294
Prednisolone Acetate26$758
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat31$563
Dorzolamide Hcl16$419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$246$80,69888 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$291$69,95678 claims
Aerie Pharmaceuticals, Inc.Rocklatan$207$34,98761 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$49$25,71814 claims
Sun Pharmaceutical Industries Inc.Cequa$105$11,27316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,122 optometrist providers in Tennessee.

Other optometrist in Tullahoma

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →